Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3217740 | 0.85 | — | — | |
| SCHEMBL3216697 | 0.85 | CYP1A2 (0.32) | SMN1; SMN2 | |
| SCHEMBL3202405 | 0.81 | MAOA (0.30) | — | |
| SCHEMBL3211699 | 0.81 | KDM4E (0.36) | — | |
| SCHEMBL3203961 | 0.80 | SMN1; SMN2 (0.32) | SMN1; SMN2 | |
| SCHEMBL3201923 | 0.80 | KDM4E (0.36) | SMN1; SMN2 | |
| SCHEMBL3203931 | 0.80 | CYP1A2 (0.30) | — | |
| SCHEMBL3200969 | 0.74 | — | — | |
| SCHEMBL3212243 | 0.73 | KDM4E (0.38) | — | |
| SCHEMBL3209603 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7732643-B2 | Transition metal complex, catalyst for olefin polymerization, and process for producing olefin polymer with the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-06-08 | — | — | US | disclosed |
| US-7671226-B2 | Transition metal complex, catalyst for olefin polymerization, and process for producing olefin polymer with the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-03-02 | — | — | US | disclosed |
| US-20100048933-A1 | TRANSITION METAL COMPLEX, CATALYST FOR OLEFIN POLYMERIZATION, AND PROCESS FOR PRODUCING OLEFIN POLYMER WITH THE SAME | HANAOKA HIDENORI | 2010-02-25 | — | — | US | disclosed |
| EP-1426379-B1 | TRANSITION METAL COMPLEX,CATALYST FOR OLEFIN POLYMERIZATION, AND PROCESS FOR PRODUCING OLEFIN POLYMER WITH THE SAME | SUMITOMO CHEMICAL CO (JP) | 2009-11-11 | — | — | EP | disclosed |
| US-20090054607-A1 | Transition metal complex, catalyst for olefin polymerization, and process for producing olefin polymer with the same | HANAOKA HIDENORI | 2009-02-26 | — | — | US | disclosed |
| US-7439379-B2 | Transition metal complex, catalyst for olefin polymerization, and process for producing olefin polymer with the same | SUMITOMO CHEMICAL CO., LTD. (JP) | 2008-10-21 | — | — | US | disclosed |
| US-20040242410-A1 | Transition metal complex, catalyst for olefin polymerization, and process for producing olefin polymer with the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-12-02 | — | — | US | disclosed |
| EP-1426379-A1 | TRANSITION METAL COMPLEX,CATALYST FOR OLEFIN POLYMERIZATION, AND PROCESS FOR PRODUCING OLEFIN POLYMER WITH THE SAME | Sumitomo Chemical Company, Limited (JP) | 2004-06-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054607-A1 | Transition metal complex, catalyst for olefin polymerization, and process for producing olefin polymer with the same | C1R, C1S, AP1M1 | SMN1; SMN2 3599/4885 |
| US-20100048933-A1 | TRANSITION METAL COMPLEX, CATALYST FOR OLEFIN POLYMERIZATION, AND PROCESS FOR PRODUCING OLEFIN POLYMER WITH THE SAME | C1R, C1S, AP1M1 | SMN1; SMN2 3599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.